{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:54:51Z","timestamp":1740164091537,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77111-4","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:29:30Z","timestamp":1735583370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF study"],"prefix":"10.1038","volume":"14","author":[{"given":"Marat","family":"Fudim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Linz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calum","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Kimmeskamp-Kirschbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mondritzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Tinel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"1","key":"77111_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/01.CIR.0000105721.71640.DA","volume":"109","author":"M Li","year":"2004","unstructured":"Li, M. et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109(1), 120\u2013124 (2004).","journal-title":"Circulation"},{"key":"77111_CR2","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ .Heart Fail. 2(6), 692\u2013699  (2009).","DOI":"10.1161\/CIRCHEARTFAILURE.109.873968"},{"key":"77111_CR3","doi-asserted-by":"crossref","unstructured":"Sabbah, H. N. et al. Vagus nerve stimulation in experimental heart failure. Heart Fail. Rev. 16(2), 171\u2013178 (2011).","DOI":"10.1007\/s10741-010-9209-z"},{"key":"77111_CR4","doi-asserted-by":"crossref","unstructured":"La Rovere, M. T. et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J. Am. Coll. Cardiol. 53(2), 193\u2013199 (2009).","DOI":"10.1016\/j.jacc.2008.09.034"},{"key":"77111_CR5","doi-asserted-by":"publisher","unstructured":"Hristopher, C. et al. Heart-rate recovery immediately after exercise as a predictor of mortality.N. Engl. J. Med. 341(18), 1351\u20131357 (1999). https:\/\/doi.org\/10.1056\/NEJM199910283411804 (1999).","DOI":"10.1056\/NEJM199910283411804"},{"key":"77111_CR6","doi-asserted-by":"publisher","unstructured":"Qiu, S. et al. Heart rate recovery and risk of cardiovascular events and all-cause mortality: a meta\u2010analysis of prospective cohort studies. J. Am. Heart Assoc. 6(5). https:\/\/doi.org\/10.1161\/JAHA.117.005505 (2017).","DOI":"10.1161\/JAHA.117.005505"},{"key":"77111_CR7","doi-asserted-by":"crossref","unstructured":"Binkley, P. F. et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J. Am. Coll. Cardiol. 21(3), 655\u2013661 (1993).","DOI":"10.1016\/0735-1097(93)90098-L"},{"key":"77111_CR8","doi-asserted-by":"crossref","unstructured":"Desai, M. Y., Watanabe, M. A., Laddu, A. A. & Hauptman, P. J. Pharmacologic modulation of parasympathetic activity in heart failure. Heart Fail. Rev. 16(2), 179\u2013193 (2011).","DOI":"10.1007\/s10741-010-9195-1"},{"key":"77111_CR9","doi-asserted-by":"crossref","unstructured":"Tsao, C. W. et al. Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association. Circulation 147(8): e93\u2013e621 (2023).","DOI":"10.1161\/CIR.0000000000001137"},{"key":"77111_CR10","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42(36), 3599\u20133726 (2021)."},{"key":"77111_CR11","doi-asserted-by":"crossref","unstructured":"La Rovere, M. T., Bigger, J. T., Marcus, F. I., Mortara, A. & Schwartz, P. J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet  351(9101), 478\u2013484 (1998).","DOI":"10.1016\/S0140-6736(97)11144-8"},{"key":"77111_CR12","doi-asserted-by":"publisher","unstructured":"Vakalopoulos A. et al. Discovery of BAY 2413555, First Selective Positive Allosteric Modulator of the M2 Receptor toRestore Cardiac Autonomic Balance. J Med Chem. PMID: 39463278.  https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01590. (Epub ahead of print).","DOI":"10.1021\/acs.jmedchem.4c01590"},{"issue":"1","key":"77111_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jelectrocard.2011.06.003","volume":"45","author":"EZ Soliman","year":"2012","unstructured":"Soliman, E. Z. & Rautaharju, P. M. Heart rate adjustment of PR interval in middle-aged and older adults. J. Electrocardiol. 45(1), 66\u201369 (2012).","journal-title":"J. Electrocardiol."},{"issue":"1","key":"77111_CR14","doi-asserted-by":"publisher","first-page":"H8","DOI":"10.1152\/ajpheart.00335.2007","volume":"293","author":"M Buchheit","year":"2007","unstructured":"Buchheit, M., Papelier, Y., Laursen, P. B. & Ahmaidi, S. Noninvasive assessment of cardiac parasympathetic function: Postexercise heart rate recovery or heart rate variability? Am. J. Physiol. Heart Circ. Physiol. 293(1), H8\u2013H10 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"77111_CR15","doi-asserted-by":"publisher","unstructured":"Velmeden, D. et al. Abstract 11446: The role of heart rate recovery in chronic heart failure\u2014Results from the Myovasc study. Circulation 144(Suppl_1). https:\/\/doi.org\/10.1161\/circ.144.suppl_1.11446 (2021).","DOI":"10.1161\/circ.144.suppl_1.11446"},{"key":"77111_CR16","doi-asserted-by":"crossref","unstructured":"Vinik, A. I., Erbas, T. & Casellini, C. M. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J. Diabetes Investig. 4(1), 4\u201318 (2013).","DOI":"10.1111\/jdi.12042"},{"key":"77111_CR17","doi-asserted-by":"crossref","unstructured":"Del Buono, M. G. et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73(17), 2209\u20132225 (2019).","DOI":"10.1016\/j.jacc.2019.01.072"},{"key":"77111_CR18","doi-asserted-by":"crossref","unstructured":"Borlaug, B. A. et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114(20), 2138\u20132147 (2006).","DOI":"10.1161\/CIRCULATIONAHA.106.632745"},{"issue":"11","key":"77111_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.921","volume":"19","author":"M van Bilsen","year":"2017","unstructured":"van Bilsen, M. et al. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 19 (11), 1361\u20131378 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"77111_CR20","doi-asserted-by":"crossref","unstructured":"Khuanjing, T., Palee, S., Chattipakorn, S. C. & Chattipakorn, N. The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: from cells to patient reports. Acta Physiol. (Oxf). 228(2), e13396 (2020).","DOI":"10.1111\/apha.13396"},{"key":"77111_CR21","doi-asserted-by":"crossref","unstructured":"Brouwer, J. & Van Veldhuisen, D. J. Man In \u2019t Veld AJ, Dunselman PHJM, Boomsma F, Haaksma J, et al. Heart rate variability in patients with mild to moderate heart failure: Effects of neurohormonal modulation by digoxin and ibopamine. J. Am. Coll. Cardiol. 26(4), 983\u2013990. (1995).","DOI":"10.1016\/0735-1097(95)00285-3"},{"key":"77111_CR22","doi-asserted-by":"crossref","unstructured":"Groehs, R. V. et al. Exercise training prevents the deterioration in the arterial baroreflex control of sympathetic nerve activity in chronic heart failure patients. Am. J. Physiol. Heart Circ. Physiol. 308(9), H1096\u2013H1102 (2015).","DOI":"10.1152\/ajpheart.00723.2014"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77111-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:03:04Z","timestamp":1735639384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77111-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77111"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77111-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fudim was supported by Bayer. Muhammad Shahzeb Khan reports fees from Bayer. JoAnn Lindenfeld has received grant funding from AstraZeneca and consulting fees from Abbott, Alleviant, Axon, Astra Zeneca, Boston Scientific, CVRx, Medtronic, Merck, Edwards Lifesciences, Whiteswell, Vascular Dynamics, Cordio, VWave. Calum MacRae has received grant funding from the American Heart Association, Apple, AstraZeneca, Bayer, Biosymetrics, Dewpoint Therapeutics, DinaQor, Dr. Evidence, Foresite Labs, Janssen, Pfizer, Platform Life Sciences, Samsung, Verily, Quest Diagnostics and is a co-founder of Atman Health and Tanaist. Nina Kimmeskamp-Kirschbaum, Michaela Meyer, Thomas Mondritzki, and Hanna Tinel are employees of Bayer AG and may own stock in the company. Wilfried Dinh was a full-time employee of Bayer AG during the conduct of the trial and may own stock in the company. Robert J Mentz has received research support and\/or honoraria from Novartis, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novo Nordisk, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. Dominik Linz has no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31585"}}